{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-022361","form_type":"8-K","ticker":"OTLC","cik":"0000908259","company_name":"Oncotelic Therapeutics, Inc.","filed_at":"2025-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.657997+00:00","generated_at":"2026-05-17T20:18:47.587520+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Oncotelic secures $560K convertible note from Mast Hill; enters $25M equity purchase agreement","bullets":["Issued $560,000 convertible promissory note to Mast Hill Fund, 10% OID, 10% interest, convertible at $0.07/share.","Note warrants issued for 2,000,000 shares at $0.15 exercise price; note secured against most company assets.","Also entered $25M equity purchase agreement with Mast Hill; issued warrants for 3,350,000 shares.","Equity purchase price set at 97% of market price or 102% of market alternative price; commitment period up to 24 months.","Proceeds from note for general working capital; registration rights agreements filed for resale of underlying shares."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-022361","json":"https://secwatch.observer/filing/0001641172-25-022361.json","markdown":"https://secwatch.observer/filing/0001641172-25-022361.md","text":"https://secwatch.observer/filing/0001641172-25-022361.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/908259/000164117225022361/0001641172-25-022361-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/908259/000164117225022361/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T20:18:47.587520+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"873721c81a3629b9812e21c41fdf877052d26368","claim":"Oncotelic Therapeutics, Inc. incurred convertible notes of $560,000 with Mast Hill Fund, LP at 10% per annum maturing earlier of (a) one-year anniversary of the date of the 2025 Mast Hill Purchase Agreement, or (b) acceleration by Mast Hill upon Event of Default, or (c) on prep.","evidence_excerpt":"On July 31, 2025, Oncotelic Therapeutics, Inc. (the “Company” or “Our”) entered into a Securities Purchase Agreement (the “2025 Mast Hill Purchase Agreement ”), with Mast Hill Fund, LP (“ Mast Hill ”), and the Company issued a convertible promissory note in the aggregate gross principal amount of $560,000 (the “ 2025 Mast Hill Note ”).","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/908259/000164117225022361/0001641172-25-022361-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$560,000"},{"label":"Counterparty","value":"Mast Hill Fund, LP"},{"label":"Rate","value":"10% per annum"},{"label":"Maturity","value":"earlier of (a) one-year anniversary of the date of the 2025 Mast Hill Purchase Agreement, or (b) acceleration by Mast Hill upon Event of Default, or (c) on prep"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}